Annual report for Suven Pharmaceuticals Ltd. for FY-2020
18-06-2020
Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to above subject, please find enclosed herewith an invitation for conducting the conference call for investors on Friday, June 19, 2020 at 12:30 p.m. IST to discuss the Audited Financial Results for the Q4 Financial Year 2020, to be declared on 18th June, 2020.17-06-2020
Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In continuation to our letter dated June 15, 2020 regarding to Notice of Board Meeting, please find enclosed the copies of the newspaper advertisements as appeared today i.e. June 16, 2020 in Business Standard and Andhra Prabha (Telugu). The above information will also be hosted on the website of the Company at: https://www.suvenpharm.com/index.php/investors/corporate-info/Advertisements16-06-2020
Suven Pharmaceuticals Ltd - 543064 - Board Meeting Intimation for Intimation Of Board Meeting Of The Company To Be Held On Thursday, The 18Th June,2020
Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/06/2020 ,inter alia, to consider and approve With reference to above subject, pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that a Meeting of the Board of Directors of the Company will be held on Thursday, the 18th June, 2020 at 11:30 a.m. at the Registered Office, SDE Serene Chambers, 3rd Floor, Road No 5, Banjara Hills, Hyderabad - 500034 of the Company, to consider, among other things, inter alia, and take on record the following matter(s): ? To consider and approve the Audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the fourth quarter and for the year ended March 31, 2020 and related matters. Please further note that TRADING WINDOW for dealing in the securities of the company is already closed from 01st April, 2020 as per PIT Code of the Company. Trading window will be opened from 22nd June, 2020.15-06-2020
Suven Pharmaceuticals Ltd - 543064 - Statement Of Investor Complaints For The Quarter Ended March 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0990 Name of the Signatory :- K HANUMANTHA RAODesignation :- Company Secretary and Compliance Officer08-05-2020
Suven Pharmaceuticals Ltd - 543064 - Clarification On Intimation Of Fire Incident Occurred On 26Th April, 2020
We refer to your email and further to our intimation dated 27th April, 2020 about the fire incident in our R&D; labs in Jeedimetla Unit of our Company, we hereby clarify that damage to all the equipments, furniture & fixtures is estimated around Rs 18.00 Crores and were fully insured. There is no impact on the operations in Jeedimetla Unit.29-04-2020
Suven Pharmaceuticals Ltd - 543064 - Intimation Of Fire Incidence At Jeedimetla Unit In Hyderabad
We wish to inform you that the Suven Pharmaceuticals experienced a fire incidence occurred on April 26, 2020 in the evening at our Jeedimetla facility. Although there was damage to the labs in one of the building, there were no injuries or casualties. While the exact cause remains under investigation, we know the fire started in one lab in one of the buildings. Fewer staff were on site because it was Sunday, but those that were present followed their training and were able to successfully contain the incident to one portion of that building only until the fire tenders arrived. As a result of the effectiveness of those safeguards and the decisive actions of our employees, the facility is still operational other than that building. Suven will provide additional updates when more information becomes available.27-04-2020
Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Credit Rating
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we wish to intimate you that the CRISIL has assigned the following ratings to the Bank facilities of our Company vide its letter dated April 24, 2020.24-04-2020
Suven Pharmaceuticals Ltd - 543064 - Shareholding for the Period Ended March 31, 2020
Suven Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click here14-04-2020
Suven Pharmaceuticals Ltd - 543064 - Submission Of Compliance Certificate Under Regulation 7(3) Of SEBI (LODR) Regulations, 2015 For The Half-Year Ended 31St March, 2020
With reference to the above subject, please find enclosed compliance certificate for the half-year ended 31st March, 2020 duly signed by the Compliance Officer and authorised representative of the Share Transfer Agent (KFin Technologies Private Limited, Hyderabad), under Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.14-04-2020